First Author: R.Sorkhabi IRAN
Co Author(s): M. Ahoor Y. Amizadeh
Purpose:
Glaucoma is a common degenerative process of retinal ganglion cells which causes impaired vision. As a modifiable factor, IOP is controlled by variety of medical and surgical modalities while the costs are a problematic matter. Prostaglandin derivatives are proved to be the most potent and long-acting agents while the most expensive ones. Therefore, checking the less frequent doses of this medication e.g. every other day, is warranted due to high possibility of invaluable outcomes.
Setting:
Tabriz University of Medical Sciences
Methods:
Study was a randomized double-masked controlled trial and 53 cases of well-controlled primary and secondary open angle glaucoma were entered to study. Lataprost ophthalmic solution 0.005% (Iranian brand of latanoprost) one drop at bed-time should have consumed by the patients. After recovery of 3 normal consecutive IOPs, the dosage was altered to one drop every other day at bed-time and they closely monitored at 1st, 2nd, 4th, 6th, 8th and 12th weeks within second phase of the study and IOPs were measured. As soon as an abnormally elevated IOP was encountered, patient was excluded from study and the prior regimen was reestablished.
Results:
53 eyes of 53 patients were included in our study. 27 of them suffered primary open angle glaucoma and 26 patients had secondary open angle glaucoma which most of them were pseudoexpholiative glaucoma. Their age ranges from 52 to 82 year old individuals. 29 and 24 cases were males and females respectively and their mean age ± standard deviations were 67.41 ± 8.94 and 63.96 ± 8.31 years. After beginning the second phase of study, a mild trend of increasing IOP is recordable. A corresponding trend was even detected in female and male patients separately. The P values at 1st, 2nd, 4th, 6th, 8thand 12th weeks were 0.003, 0.001, 0.000, 0.000, 0.000 and 0.000 respectively. In the first 2 weeks after initiation of the 2nd phase, 66%
Conclusions:
of cases have no change in IOPs, but thereafter, 69.8%, experienced increasing IOPs. FINANCIAL DISCLOSURE?: No
Please wait while information is loading.
